LONDON - Alizyme plc landed the speciality pharma company Norgine BV as a European marketing partner for Colal-Pred, its treatment for ulcerative colitis. The deal has a headline value of €42.75 million (US$67.4 million), of which €2 million will be paid up front. (BioWorld Today) Read More
